ANRO:NYE-Alto Neuroscience, Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 12.1

Change

0.00 (0.00)%

Market Cap

USD 0.37B

Volume

0.20M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 555.27B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 4.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.51B
NUVB Nuvation Bio Inc

N/A

USD 0.80B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.45B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.19B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B

ETFs Containing ANRO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.37B 82% B 43% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.